Between September 1988 and August 1990, we treated 35 @entity1 with metastatic @entity0 with a novel regimen containing @entity2664 , @entity1487 ( @entity1487 ), and high-dose leucovorin. This regimen was designed to take full advantage of the favorable @entity137 profiles of these agents while maintaining a high level of activity. All @entity1 had received previous chemotherapy (adjuvant only, 15 @entity1 ; at least one metastatic regimen, 20 @entity1 ). Seven @entity1 had received previous @entity632 , but none within 6 months of study entry. Of 31 assessable @entity1 , 20 (65%) had objective responses (two complete, 18 partial), with a median response duration of 6 months (range, 3 to 16+ months). Four @entity1 with bone @entity3 (abnormal bone scan only) and @entity158 were not considered assessable by strict response criteria; two of these @entity1 had sustained symptomatic relief for 6 and 8 months, respectively. Myelosuppression was the most frequent @entity137 but was mild in most @entity1 ; only four hospitalizations for @entity221 and @entity1398 were required (2% of courses). No severe @entity882 occurred and no RBC transfusions were required. @entity1665 , @entity33 , and @entity390 / @entity391 were uncommon and were not severe in any @entity1 . The combination of @entity2664 , @entity1487 , and high-dose leucovorin is well tolerated and active as a first- or second-line treatment for metastatic @entity0 . Comparison with other standard regimens for @entity0 is indicated.

@entity2664 , @entity1487 , and high-dose leucovorin: an effective, well-tolerated regimen for metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['Alopecia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', 'fluorouracil']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
